# BenQ BM Holding Cayman Corp.
# 明基醫院集團股份有限公司

*(A company incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2581)**

# INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

## FINANCIAL HIGHLIGHTS

| | Six Months Ended June 30, | | |
|---|---|---|---|
| | **2026** | 2025 | Changes |
| | ***RMB '000*** | *RMB '000* | *%* |
| | ***(unaudited)*** | *(audited)* | |
| Revenue | **1,343,552** | 1,312,316 | 2.4% |
| Gross profit | **180,670** | 208,633 | -13.4% |
| Profit for the period | **20,814** | 48,704 | -57.3% |
| Basic and diluted earnings per share (in RMB) | **0.07** | 0.20 | -65.0% |

The board (the "**Board**") of directors (the "**Directors**") of BenQ BM Holding Cayman Corp. (the "**Company**", together with its subsidiaries, collectively, the "**Group**") is pleased to announce the interim results of the Group for the six months ended June 30, 2026 (the "**Reporting Period**"), together with comparative figures for the six months ended June 30, 2025 (the "**Previous Period**") as follows:

## CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
**For the six months ended June 30, 2026**

| | *Note* | **2026** *RMB '000* *(unaudited)* | 2025 *RMB '000* *(audited)* |
|---|---|---|---|
| **Revenue** | 4 | **1,343,552** | 1,312,316 |
| Cost of revenue | | **(1,162,882)** | (1,103,683) |
| **Gross profit** | | **180,670** | 208,633 |
| Other net gain | 5 | **951** | 1,887 |
| Selling and distribution expenses | | **(3,584)** | (3,072) |
| Administrative expenses | | **(138,114)** | (132,413) |
| Reversal/(provision) of impairment losses on trade receivables | | **1,272** | (39) |
| **Profit from operations** | | **41,195** | 74,996 |
| Net finance costs | 6(a) | **5,106** | (4,259) |
| Share of losses of associates | | **(12,344)** | (309) |
| **Profit before taxation** | 6 | **33,957** | 70,428 |
| Income tax expense | 7 | **(13,143)** | (21,724) |
| **Profit attributable to equity shareholders of the Company** | | **20,814** | 48,704 |
| **Earnings per share (RMB)** | 8 | | |
| Basic (RMB) | | **0.07** | 0.20 |
| Diluted (RMB) | | **0.07** | 0.20 |

## CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

**For the six months ended June 30, 2026**

| | **2026** | 2025 |
|---|---|---|
| | ***RMB '000*** | *RMB '000* |
| | ***(unaudited)*** | *(audited)* |
| **Profit for the period** | **20,814** | 48,704 |
| **Other comprehensive income for the period (after tax and reclassification adjustments)** | | |
| Item that will not be reclassified to profit or loss: | | |
| Exchange differences on translation of | | |
| – financial statements of the Company with functional currency other than RMB | **(16,157)** | 8 |
| Item that may be reclassified subsequently to profit or loss: | | |
| Exchange differences on translation of | | |
| – financial statements of subsidiaries with functional currencies other than RMB | **(995)** | 276 |
| **Other comprehensive (loss)/income for the period** | **(17,152)** | 284 |
| **Total comprehensive income for the period attributable to equity shareholders of the Company** | **3,662** | 48,988 |

## CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
**As at June 30, 2026**

| | *Note* | **June 30, 2026** | December 31,2025 |
|---|---|---|---|
| | | ***RMB '000*** | *RMB '000* |
| | | ***(unaudited)*** | *(audited)* |
| **Non-current assets** | | | |
| Property, plant and equipment | | **2,199,421** | 2,192,471 |
| Right-of-use assets | | **144,746** | 147,320 |
| Intangible assets | | **13,052** | 15,703 |
| Interests in associates | | **276,121** | 288,465 |
| Prepayments, deposits and other receivables | | **136,761** | 44,459 |
| Deferred tax assets | | **64,224** | 63,537 |
| | | **2,834,325** | 2,751,955 |
| **Current assets** | | | |
| Inventories | | **65,590** | 63,222 |
| Trade receivables | 9 | **268,063** | 324,918 |
| Prepayments, deposits and other receivables | | **60,664** | 60,563 |
| Time deposits | | **681** | 703 |
| Cash and cash equivalents | | **622,436** | 649,800 |
| | | **1,017,434** | 1,099,206 |
| **Current liabilities** | | | |
| Bank loans | | **574,856** | 466,094 |
| Trade payables | 10 | **451,303** | 477,356 |
| Other payables and accruals | | **332,840** | 381,405 |
| Contract liabilities | | **28,984** | 30,692 |
| Current taxation | | **32,212** | 38,499 |
| | | **1,420,195** | 1,394,046 |
| **Net current liabilities** | | **(402,761)** | (294,840) |
| **Total assets less current liabilities** | | **2,431,564** | 2,457,115 |

**CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)**
**As at June 30, 2026**

| | *Note* | **June 30, 2026** | December 31,2025 |
|---|---|---|---|
| | | ***RMB ’000*** | *RMB ’000* |
| | | ***(unaudited)*** | *(audited)* |
| **Non-current liabilities** | | | |
| Bank loans | | **175,399** | 204,981 |
| | | **175,399** | 204,981 |
| **NET ASSETS** | | **2,256,165** | 2,252,134 |
| **CAPITAL AND RESERVES** | | | |
| Share capital | 11 | **2,073,352** | 2,073,352 |
| Reserves | | **182,813** | 178,782 |
| **TOTAL EQUITY** | | **2,256,165** | 2,252,134 |

## NOTES TO THE FINANCIAL STATEMENTS

*(Expressed in RMB unless otherwise indicated)*

### 1. GENERAL INFORMATION

BenQ BM Holding Cayman Corp. (the "Company") was incorporated in Cayman Islands on January 5, 2009 as an exempted company with limited liability under the Companies Act, Cap 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands. The Company's shares were listed on The Main Board of the Stock Exchange of Hong Kong Limited on December 22, 2025.

The Company is an investment holding company. The Company and its subsidiaries (together, "the Group") are principally engaged in the provision of healthcare services through the multi-disciplinary private for-profit general hospitals in the People's Republic of China (the "PRC").

### 2. Basis of preparation of the financial statements

The unaudited interim financial information set out in this announcement does not constitute the unaudited interim financial report of the Group but is extracted from the unaudited interim financial report.

The interim financial report of the Group has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with International Accounting Standard ("IAS") 34, Interim financial reporting, issued by the International Accounting Standards Board ("IASB"). It was authorized for issue on August 6, 2026.

The interim financial report has been prepared in accordance with the same material accounting policies adopted in the 2025 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2026 annual financial statements. Details of any changes in accounting policies are set out in Note 3.

The preparation of an interim financial report in conformity with IAS 34 requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a period to date basis. Actual results may differ from these estimates.

The interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2025 annual financial statements. The condensed consolidated interim financial statements and notes thereon do not include all of the information required for a full set of financial statements prepared in accordance with IFRS Accounting Standards.

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, Review of interim financial information performed by the independent auditor of the entity, issued by the Hong Kong Institute of Certified Public Accountants.

The financial information relating to the financial year ended December 31, 2025 that is included in the interim financial report as comparative information does not constitute the Company's annual consolidated financial statements for that financial year but is derived from those financial statements. The Company's auditor has reported on those financial statements. The auditor's report was unqualified and did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying its report.

The condensed consolidated financial statements have been prepared assuming the Group will continue as a going concern notwithstanding the net current liabilities of the Group of RMB402,761,000 at June 30, 2026. The directors of the Company are of the opinion that the Group is able to meet in full its financial obligations as they fall due for at least the next twelve months from June 30, 2026, having taken into account the factors including: (1) the Group's cash flow forecast covering a period of not less than twelve months from June 30, 2026 and (2) the Group's unused banking facilities as at June 30, 2026. Accordingly, the directors of the Company consider it is appropriate to prepare the consolidated financial statements on a going concern basis.

## 3. Changes in accounting policies

The IASB has issued a number of amendments to IFRS Accounting Standards that are first effective for the current accounting period. Of these, only the amendments to IFRS 9, *Financial instruments* and IFRS 7, *Financial instruments: Disclosures – Amendments to the classification and measurement of financial instruments*, are relevant to the Group's financial statements. The impacts of adopting these amendments are discussed below.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

Amendments to IFRS 9, *Financial instruments* and IFRS 7, *Financial instruments: Disclosures – Amendments to the classification and measurement of financial instruments*.

The amendments cover three main aspects:

– The amendments clarify when a financial asset or a financial liability is recognised and derecognised. They also introduce an optional exception that permits an entity to derecognise a financial liability before the settlement date when the financial liability is settled in cash using an electronic payment system, provided that specific criteria are met.

– For the assessment of whether a financial asset has contractual cash flows that are solely payments of principal and interest on the principal amount outstanding, the amendments clarify the assessment of interest and introduce an additional test for the financial assets with contingent features, for example environmental, social or governance ("ESG")-linked features. The amendments also clarify the difference between financial assets with non-recourse features and contractually linked instruments which may then change the applicable assessments.

– The amendments introduce new disclosures for disposals of investments in equity instruments designated at FVOCI, and for financial instruments not measured at FVPL which contain contractual terms that could change the amount of contractual cash flows based on the occurrence or non-occurrence of a contingent event that does not relate directly to changes in basic lending risks and costs.

Upon adoption of the amendments, the Group has elected to apply the exception for the derecognition of certain trade payables settled in cash using qualifying electronic payment systems. Under the exception, these trade payables are derecognised when the Group initiates a payment instruction through a qualifying electronic payment system and, as a result, no longer has the practical ability to withdraw, stop, or cancel the payment instruction and to access the cash to be used for settlement, and the settlement risk associated with the payment system is insignificant. The Group has applied this election consistently to all settlements made through the same qualifying electronic payment system.

The Group has applied the amendments retrospectively. As permitted by the transition requirements, the Group has not restated prior periods. The application of the exception does not have a material impact on the Group's consolidated financial statements for the periods presented.

The amendments would also affect the disclosures to be included in the Group's annual financial statements for the year ending December 31, 2026 in respect of investments in equity instruments designated at FVOCI and financial instruments not measured at FVPL with specified contingent features. No additional disclosure has been included in this announcement.

## 4. REVENUE AND SEGMENT REPORTING

### (a) Revenue

The Group is principally engaged in hospital healthcare service.

#### *(i) Disaggregation of revenue*

Disaggregation of revenue from contracts with customers by service lines is as follows:

| | Six months ended 30 June | |
|---|---|---|
| | **2026** | 2025 |
| | ***RMB '000*** | *RMB '000* |
| | ***(unaudited)*** | *(audited)* |
| **Revenue from contracts with customers within the scope of IFRS 15** | | |
| Hospital healthcare services | | |
| – Out-patient services | **607,988** | 603,134 |
| – In-patient services | **720,006** | 695,653 |
| Others | **4,442** | 4,213 |
| | **1,332,436** | 1,303,000 |
| **Revenue from other sources** | | |
| Rental income | | |
| – Lease payments that are fixed or depend on an index or a rate | **8,194** | 6,599 |
| – Variable lease payments that do not depend on an index or a rate | **2,922** | 2,717 |
| | **1,343,552** | 1,312,316 |

Disaggregation of revenue from contracts with customers by the timing of revenue recognition is as follow:

| | Six months ended 30 June | |
|---|---|---|
| | **2026** | 2025 |
| | ***RMB '000*** | *RMB '000* |
| | ***(unaudited)*** | *(audited)* |
| **Disaggregated by timing of revenue recognition** | | |
| Point in time | **612,430** | 607,347 |
| Over time | **720,006** | 695,653 |
| | **1,332,436** | 1,303,000 |

The Group's customer base is diversified and there is no single customer with whom transactions have exceeded 10% of the Group's revenue for the six months ended June 30, 2026 (for the six months ended June 30, 2025: nil).

***(ii) Revenue expected to be recognized in the future arising from contracts with customers in existence at the reporting date***

The Group has applied the practical expedient in paragraph 121 of IFRS 15 and therefore the information about remaining performance obligations is not disclosed for contracts that have an expected duration of one year or less.

**(b) Segment reporting**

***(i) Segment information***

The Group manages its businesses as a whole by the Group's most senior executive management for the purposes of resource allocation and performance assessment. The Group's chief operating decision maker is the chief executive officer of the Group who reviews the Group's combined results of operations in assessing performance of and making decisions about allocations to this segment.

Accordingly, the Group has only one reportable segment and no further analysis of this single segment is presented.

***(ii) Geographic information***

No geographical information is shown as the revenue and profit from operations of the Group is substantially all derived from activities in the PRC and substantially all of the Group's property, plant and equipment are located physically or operationally in the PRC.

## 5. OTHER NET GAIN

| | Six months ended 30 June | |
|---|---|---|
| | **2026** | 2025 |
| | ***RMB ’000*** | *RMB ’000* |
| | ***(unaudited)*** | *(audited)* |
| Government grants (Note) | **2,082** | 1,180 |
| Net foreign exchange gain/(loss) | **152** | (807) |
| Net loss on disposal of property, plant and equipment | **(820)** | (13) |
| Others | **(463)** | 1,527 |
| | **951** | **1,887** |

*Note:* The government grants are mainly unconditional government subsidies received by certain subsidiaries of the Group in consideration of their tax contribution and to support the hospital development.

## 6. PROFIT BEFORE TAXATION

Profit before taxation is arrived at after (crediting)/charging:

### (a) Net finance costs

| | Six months ended 30 June | |
|---|---|---|
| | **2026** | 2025 |
| | ***RMB ’000*** | *RMB ’000* |
| | ***(unaudited)*** | *(audited)* |
| **Finance income:** | | |
| Interest income | **(11,297)** | (1,433) |
| **Finance costs:** | | |
| Interest expenses on bank loans | **7,438** | 9,767 |
| Less: interest expense capitalized into construction in progress* | **(1,247)** | (4,075) |
| | **6,191** | 5,692 |
| | **(5,106)** | 4,259 |

The borrowing costs have been capitalized at a rate range of 2.11%-2.26% per annum for the six months ended June 30, 2026 (six months ended June 30, 2025: 2.29% -2.36%).

**(b) Staff costs**

| | Six months ended 30 June | |
|---|---|---|
| | **2026** | 2025 |
| | ***RMB '000*** | *RMB '000* |
| | ***(unaudited)*** | *(audited)* |
| Salaries, wages and other benefits | **433,208** | 421,200 |
| Contributions to defined contribution retirement plan | **46,242** | 47,527 |
| Equity settled share-based payment expenses | **369** | 1,160 |
| | **479,818** | 469,887 |

Pursuant to the relevant labor rules and regulations in the PRC, the Group's PRC subsidiaries participate in defined contribution retirement benefit schemes (the "Schemes") organized by the local government authorities whereby the Group's PRC subsidiaries are required to make contributions to the Schemes based on certain percentages of the eligible employee's salaries. The local government authorities are responsible for the entire pension obligations payable to the retired employees.

The Group has no other material obligation for the payment of retirement benefits beyond the contributions described above.

**(c) Other items**

| | Six months ended 30 June | |
|---|---|---|
| | **2026** | 2025 |
| | ***RMB '000*** | *RMB '000* |
| | ***(unaudited)*** | *(audited)* |
| Depreciation and amortization | | |
| – owned property, plant and equipment | **93,111** | 82,682 |
| – right-of-use assets | **2,574** | 2,574 |
| – intangible assets | **5,561** | 6,235 |
| | **101,246** | 91,491 |
| Listing expenses | – | 4,488 |
| Cost of inventories (representing pharmaceutical products and consumables used, included in cost of revenue) | **544,283** | 508,730 |

## 7. INCOME TAX IN THE CONSOLIDATED STATEMENT OF PROFIT OR LOSS

### (a) Taxation in the consolidated statement of profit or loss represents:

| | Six months ended 30 June | |
|---|---|---|
| | **2026** | 2025 |
| | ***RMB '000*** | *RMB '000* |
| | ***(unaudited)*** | *(audited)* |
| **Current tax – PRC Corporate Income Tax** | | |
| Provision for the six months | **13,830** | 23,008 |
| **Deferred tax** | | |
| Reversal and origination of temporary differences | **(687)** | (1,284) |
| | **13,143** | 21,724 |

*Notes:*

(i) Pursuant to the rules and regulations of the Cayman Islands, the Company is not subject to any income tax in the Cayman Islands.

(ii) Pursuant to the income tax rules and regulations of the Malaysia Labuan ("LBU"), the Group's subsidiary in the LBU was a Labuan Holding Company, which was liable to the Malaysia corporation tax at a rate of 3% or a flat rate of MYR20,000 per annum. No provision for Labuan Profits tax was made for the subsidiary as it did not have any assessable profits subject to Labuan Profits Tax during the six months ended June 30, 2026 (six months ended June 30, 2025: nil).

(iii) The subsidiary of the Group incorporated in Taiwan, province of the PRC ("Taiwan") is liable to Taiwan Profits Tax at a rate of 20%. No provision for Taiwan Profits Tax was made for the subsidiary as it did not have any assessable profits subject to Taiwan Profits Tax during the six months ended June 30, 2026 (six months ended June 30, 2025: nil).

(iv) The Group's subsidiaries in Mainland China are subject to Corporate Income Tax ("CIT") at a statutory rate of 25% on their respective taxable income during the six months ended June 30, 2026 (six months ended June 30, 2025: 25%).

### (b) Reconciliation between tax expense and accounting profit at applicable tax rates:

| | Six months ended 30 June | |
|---|---|---|
| | **2026** | 2025 |
| | ***RMB '000*** | *RMB '000* |
| | ***(unaudited)*** | *(audited)* |
| Profit before taxation | **33,957** | 70,428 |
| Notional tax on profit before taxation, calculated at the rates applicable to profits in the jurisdictions concerned | **10,329** | 20,348 |
| Tax effect of non-deductible expenses | **2,776** | 1,351 |
| Tax effect of unused tax losses not recognized | **38** | 25 |
| Actual tax expense | **13,143** | 21,724 |

## 8. EARNINGS PER SHARE

### (a) Basic earnings per share

The calculation of basic earnings per share is based on the profit attributable to ordinary equity shareholders of the Company of RMB20,814,000 (six months ended June 30, 2025: RMB48,704,000) and the weighted average number of ordinary shares of 311,945,001 shares (six months ended June 30, 2025: 244,945,001 shares) in issue during the interim period.

### (b) Diluted earnings per share

For the six months ended June 30, 2026, share options under the Company's Share Option Scheme were not included in the calculation of diluted earnings per share as their inclusion would have been anti-dilutive. The Company does not have other dilutive potential ordinary shares outstanding, therefore diluted earnings per share were the same as basic earnings per share.

For the six months ended June 30, 2025, the calculation of diluted earnings per share was based on the profit attributable to ordinary equity shareholders of the Company of RMB48,704,000 and the weighted average number of ordinary shares of 245,591,213 shares.

## 9. TRADE RECEIVABLES

| | **As at 30 June 2026** ***RMB '000*** ***(unaudited)*** | As at 31 December 2025 *RMB'000* *(audited)* |
|---|---|---|
| Due from related parties | **253** | 1,632 |
| Due from public medical insurance programs | **180,364** | 236,841 |
| Due from other third parties | **97,424** | 97,732 |
| | **278,041** | 336,205 |
| Less: loss allowance | **(9,978)** | (11,287) |
| | **268,063** | 324,918 |

All of the trade receivables are expected to be recovered within one year.

***Ageing analysis***

As of the end of each reporting period, the ageing analysis of trade receivables, based on the date of revenue recognition and net of loss allowance, is as follows:

| | **As at 30 June 2026** ***RMB '000*** ***(unaudited)*** | As at 31 December 2025 *RMB '000* *(audited)* |
|---|---|---|
| Within 6 months | **244,234** | 297,488 |
| Over 6 months but within 12 months | **26,463** | 29,430 |
| Over 12 months but within 18 months | **1,241** | 2,963 |
| Over 18 months | **6,103** | 6,324 |
| | **278,041** | 336,205 |
| Less: loss allowance | **(9,978)** | (11,287) |
| Trade receivables, net | **268,063** | 324,918 |

## 10. TRADE PAYABLES

| | **As at 30 June 2026** *RMB '000* *(unaudited)* | As at 31 December 2025 *RMB '000* *(audited)* |
|---|---|---|
| Due to related parties | **3,435** | 5,880 |
| Due to third parties | **447,868** | 471,476 |
| | **451,303** | 477,356 |

All of the trade and bills payables are expected to be settled within one year or are repayable on demand.

As of the end of the Reporting Period, the ageing analysis of trade and bills payables, based on the invoice date, is as follows:

| | **As at 30 June 2026** *RMB '000* *(unaudited)* | As at 31 December 2025 *RMB '000* *(audited)* |
|---|---|---|
| Within 1 year | **414,527** | 466,579 |
| Over 1 year | **36,776** | 10,777 |
| | **451,303** | 477,356 |

## 11. SHARE CAPITAL

| | **Numbers of shares** | **Share capital** ***USD*** | **Share capital** ***RMB '000*** |
|---|---|---|---|
| **Issued and fully paid** | | | |
| As at January 1, 2025 | 244,945,001 | 244,945,001 | 1,600,520 |
| Issuance of ordinary shares through initial public offering | 67,000,000 | 67,000,000 | 472,832 |
| At December 31, 2025 and June 30, 2026 | **311,945,001** | **311,945,001** | **2,073,352** |

## MANAGEMENT DISCUSSION AND ANALYSIS

### BUSINESS REVIEW

During the Reporting Period, the Group primarily provided healthcare services through Nanjing BenQ Hospital and Suzhou BenQ Hospital, both of which are located in Jiangsu Province, the PRC. The Group's revenue was primarily derived from outpatient and inpatient services. For the six months ended 30 June 2026, the Group recorded revenue from healthcare services of RMB1,327.99 million, representing an increase of approximately 2.2% from RMB1,298.79 million for the corresponding period in 2025, and accounting for approximately 98.8% of the Group's total revenue for the Reporting Period, among which, revenue from outpatient services amounted to RMB607.99 million, representing an increase of approximately 0.8% as compared with the corresponding period in 2025, while revenue from inpatient services amounted to RMB720.01 million, representing an increase of approximately 3.5% as compared with the corresponding period in 2025.

Nanjing BenQ Hospital is a tertiary Grade A Class III General Hospital with capabilities in critical care, multidisciplinary collaboration and comprehensive diagnosis and treatment. It has also obtained various national-level professional accreditations, including the National Chest Pain Center and National Stroke Center accreditations. During the Reporting Period, Nanjing BenQ Hospital continued to advance the development of its key clinical disciplines. In February 2026, its Department of Otolaryngology and Department of Rehabilitation Medicine were accredited as Jiangsu Provincial Key Clinical Specialties. As at 30 June 2026, Nanjing BenQ Hospital had one National Key Clinical Specialty, six Jiangsu Provincial Key Clinical Specialties and a number of municipal key clinical specialties, further enhancing its comprehensive clinical service capabilities and overall healthcare service standards.

Suzhou BenQ Hospital is a Class III General Hospital accredited by the Joint Commission International and has developed distinctive strengths in specialties including obstetrics and gynaecology, paediatrics and geriatric medicine. During the Reporting Period, Suzhou BenQ Hospital continued to strengthen the development of its clinical disciplines. Its Department of Rehabilitation Medicine was accredited as a Suzhou Municipal Key Clinical Specialty. Meanwhile, the hospital continued to optimise its healthcare service processes and operational management, further enhancing its healthcare service capabilities.

The Group continued to enhance its integrated healthcare service system covering critical care, the diagnosis and treatment of common diseases, multidisciplinary medical services, rehabilitation and long-term care. During the Reporting Period, the nursing homes at both the Nanjing and Suzhou campuses commenced the admission of patients, marking the Group's further expansion into nursing care services and further enhancing its integrated healthcare and rehabilitation care service network. Leveraging its existing healthcare resources, the Group will continue to steadily develop its nursing care business, enhance the continuity and comprehensiveness of its healthcare services, and continuously improve healthcare quality, clinical discipline development and operational management, thereby supporting the Group's long-term and sustainable business development.

**Scale of operation**

During the Reporting Period, the Group generated revenue primarily from providing healthcare services through its two hospitals, namely Nanjing BenQ Hospital and Suzhou BenQ Hospital. In terms of treatment processes, the Group's services can be primarily categorized into inpatient healthcare services and outpatient healthcare services. During the Reporting Period, the Group's revenue amounted to RMB1,343.6 million (Previous Period: RMB1,312.3 million) and the number of outpatient visits and inpatient visits of our hospitals were approximately 1,090,610 and 43,510, respectively, representing the respective year-on-year increase of 3.1% and 2.5%.

The following table sets forth a breakdown of key operating statistics for the two hospitals for the first six months of the year indicated:

| | 2025 | **2026** |
|---|---|---|
| **Inpatient healthcare services** | | |
| Number of registered beds | 1,850 | **2,048** |
| Effective service capacity | 334,850 | **364,328** |
| Inpatient visits (in thousand) | 42.4 | **43.5** |
| Number of inpatient surgeries | 10,947 | **11,526** |
| Average spending per inpatient visit (RMB) | 15,642 | **16,163** |
| Average bed turnover days | 7.8 | **8.4** |
| Inpatient bed-days | 325,154 | **339,656** |
| Bed occupancy rate (%) | 97.1 | **93.2** |
| **Outpatient healthcare services** | | |
| Outpatient visits (in thousand) | 1,057.4 | **1,090.6** |
| Average spending per outpatient visit (RMB) | 537 | **525** |
| Number of outpatient surgeries | 2,598 | **2,727** |

## BUSINESS PROSPECTS

Looking ahead to the second half of 2026, the Group will continue to focus on enhancing its integrated healthcare service capabilities by advancing the development of key clinical specialties, strengthening multidisciplinary collaboration, and refining its operational management, with a view to continuously improving the quality of medical services, operational efficiency and patient experience.

The Group will continue to enhance its integrated healthcare service system by leveraging the comprehensive medical resources of Nanjing BenQ Hospital and Suzhou BenQ Hospital. Building on the commencement of operations of its nursing care facilities, the Group will steadily expand its nursing care business, promote the effective integration of acute care, rehabilitation services and long-term care, and further enhance the continuity and comprehensiveness of its healthcare services.

At the same time, the Group will continue to strengthen the recruitment and development of medical professionals, advance the development of key clinical specialties and medical technology innovation, enhance its core competitiveness, and further optimize operational management and cost control to improve resource utilization and operational efficiency.

Looking forward, the Group will remain committed to its prudent and sustainable development strategy, actively capture opportunities arising from the development of the healthcare industry, and continue to drive high-quality business development while maintaining strict compliance with applicable laws and regulations and upholding a high standard of corporate governance, thereby creating long-term value for patients, employees and shareholders.

## FINANCIAL REVIEW

### Revenue

During the Reporting Period, the revenue of the inpatient healthcare services segment was RMB720.0 million, representing a year-on-year increase of 3.5% and the revenue of the outpatient healthcare services was RMB608.0 million, representing a year-on-year increase of 0.8%.

### Cost of Revenue

The cost of revenue for the Reporting Period was approximately RMB1,162.9 million, increased by approximately 5.4% year-on-year, and the increase was mainly due to (i) an increase in staff costs primarily driven by the growth in the number of doctors and other healthcare professionals during the Reporting Period. As at June 30, 2025 we had 1,012 doctors and 1,884 other medical professionals, which increased to 1,077 doctors and 1,925 other medical professionals as at June 30, 2026; and (ii) an increase in the depreciation and operating costs of Phase II of Nanjing BenQ Hospital following its commencement of operation in February 2025.

### Gross Profit and Gross Profit Margin

During the Reporting Period, gross profit was approximately RMB180.7 million, as compared to approximately RMB208.6 million in the Previous Period. Gross profit margin decreased from approximately 15.9% to approximately 13.4% as compared to the Previous Period, which was primarily attributable to (i) the commencement of operations of Phase II of Nanjing BenQ Hospital which led to an increase in depreciation and amortisation expenses by RMB9.7 million, together with an increase in maintenance and miscellaneous procurement costs of RMB2.6 million; and (ii) an increase in the number of doctors and other medical professionals during the Reporting Period which drove the staff costs up by RMB9.6 million.

### Administrative expenses

During the Reporting Period, the Group's administrative expenses totaled RMB138.1 million, increased by 4.3% year-on-year, and the increase was mainly attributable to higher labour service fees and research expenses.

**Reversal/(provision) of impairment losses on trade receivables**

During the Reporting Period, the reversal of impairment losses on trade receivables amounted to RMB1.3 million. This was mainly attributable to the partial repayment of overdue payments from group inspection entities, leading to a reduction in the balance of trade receivables.

**Net Finance Costs**

The Group's net finance costs decreased from RMB4.3 million to negative RMB5.1 million during the Reporting Period, representing a decrease of approximately 219.9% as compared to the Previous Period, which was mainly due to an increase in the average balance of cash and cash equivalents during the Reporting Period, resulting in an increase in interest income from RMB1.4 million in 2025 to RMB11.3 million in 2026, since the Group was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") at the end of December 2025, raising net proceeds of approximately HK$554.5 million.

**Share of Losses of Associates**

The Group's share of losses of associates for the Reporting Period was approximately RMB12.3 million (Previous Period: RMB0.3 million), mainly contributed by the following associates:

- Share of loss of approximately RMB7.9 million from Guigang Donghui Medical Investment Co., Ltd. (貴港市東暉醫療投資有限公司) ("**Donghui Medical**") which is primarily engaged in provision of healthcare services

- Share of loss of approximately RMB4.4 million from Nanjing Yinxia Healthcare Industry Development Co., Ltd. (南京銀廈健康產業發展有限公司) ("**Nanjing Yinxia Healthcare**"), which is primarily engaged in provision of elderly care services.

The increase in the Group's losses was mainly attributable to a year-on-year increase in the net losses of Donghui Medical and Nanjing Yinxia Healthcare. Owing to the service fee reduction implemented in the second half of 2025, Donghui Medical remained loss-making throughout 2026. Meanwhile, several building projects of Nanjing Yinxia Healthcare were completed and capitalised as fixed assets, with depreciation expenses accrued starting from the first half of 2026, resulting in substantial losses for the Reporting Period.

As disclosed in the prospectus of the Company dated December 12, 2025 (the "**Prospectus**"), the Directors expected that the receivables due from Nanjing Yinxia Healthcare of RMB68.2 million as of June 30, 2025, would be settled in the second quarter of 2026. However, as of June 30, 2026, such receivables remained outstanding because the Company was informed that there was a delay in the commercialization of the new building projects of Nanjing Yinxia Healthcare. The Directors believe that there is no recoverability issue in respect of the amount due from Nanjing Yinxia Healthcare and expect the such receivables will be settled by June 30, 2027 as soon as Nanjing Yinxia Healthcare commences commercialization and generate income.

**Income Tax Expense**

The Group's income tax expense decreased from RMB21.7 million for the Previous Period to RMB13.1 million for the Reporting Period, mainly because the profit before tax decreased from approximately RMB70.4 million for the Previous Period to approximately RMB34.0 million for the Reporting Period.

**Profit for the Period and Net Profit Margin**

The Group's profit decreased from RMB48.7 million for the Previous Period to RMB20.8 million for the Reporting Period and the net profit margin decreased from 3.7% for the Previous Period to 1.5% in the Reporting Period. The decrease was primarily due to a decrease in profit before tax.

**Liquidity, Financing and Capital Structure**

As at June 30, 2026, the Group had net current liabilities of approximately RMB402.8 million (as at December 31, 2025: approximately RMB294.8 million). The current ratio of the Group calculated based on the Group's total current assets divided by total current liabilities as at the end of the Reporting Period was approximately 0.72 times as at June 30, 2026 (as at December 31, 2025: approximately 0.79 times).

The Group finances its operations primarily through a combination of cash flows generated from operations and bank borrowings. The decrease in current ratio and bank balances was mainly attributable to substantial cash outflows from investing activities. Specifically, the Group made an upfront payment of RMB99.00 million in the first half of 2026 for the procurement of Jiangsu Province's first proton therapy device for Nanjing BenQ Hospital, under a total contract value of RMB198.00 million. This equipment will be deployed for the construction of a proton therapy centre specialising in precise radiotherapy for tumour treatment.

As at June 30, 2026, the Group had bank balances and cash of approximately RMB622.4 million (as at December 31, 2025: approximately RMB649.8 million).

As at June 30, 2026, on the basis of interest-bearing liabilities divided by total assets, the Group's gearing ratio was 19.48% (as at December 31, 2025: 17.43%).

**Exposure to Fluctuation in Exchange Rates and Other Risks**

As at June 30, 2026, the Group did not have significant foreign currency denominated operating transactions or bank borrowings. The Group's exposure to foreign currency risk mainly arose from intra-group loans denominated in USD. Based on the risk exposure arising from such intra-group loans, the Group entered into foreign exchange forward contracts for hedging purposes, with notional amounts equivalent to the outstanding balances of the relevant intercompany loans, in order to mitigate the related currency risks. Accordingly, the Group's exposure to foreign currency risk was not significant during the Reporting Period.

The Group is also exposed to other financial risks, including credit risk, liquidity risk and interest rate risk. The Group's overall risk management programme focuses on managing the unpredictability of financial markets and minimizing potential adverse impacts on the Group's financial performance.

**(a) Credit risk**

The Group's credit risk primarily arises from cash and cash equivalents, time deposits and trade and other receivables. The Group recognizes relevant impairment allowances under the expected credit loss model.

To effectively control such risks, the Group has formulated corresponding credit management policies and continuously monitors the relevant risk exposures. Cash and cash equivalents and time deposits are mainly placed with state-owned financial institutions in the PRC and reputable international financial institutions outside the PRC and Taiwan-invested banks. The management believes that the credit risk associated with these financial institutions is relatively low and there have been no recent history of default relating to such institutions.

**(b) Liquidity risk**

Liquidity risk refers to the risk that the Group may encounter insufficient funds in meeting its financial obligations as they fall due. The Group manages liquidity risk by continuously and continuously monitoring its overall financial position and cash flow situation, aiming to maintain a sufficient level of cash and cash equivalents to meet the funding needs of daily operations and capital expenditures.

The management also prudently plans the sources and timing of fund utilization in light of business development plans and capital expenditure arrangements and ensures that the Group maintains sufficient liquidity and financing flexibility through cash flow forecast, centralized fund management and bank financing arrangements.

**(c) Interest rate risk**

The Group 's interest rate risk primarily arises from interest-bearing bank borrowings. Borrowings at fixed interest rates expose the Group to fair value interest rate risk and borrowings at floating interest rates expose the Group to cash flow interest rate risk. As at June 30, 2026, the Group did not use any interest rate swap contracts or other financial instruments to hedge against interest rate risk. The management will continue to monitor changes in the interest rate market and, based on a prudent assessment of cost-effectiveness and risk exposure, will consider adopting appropriate hedging measures when necessary to mitigate the potential impact of interest rate fluctuations on the Group's financial position and operating results.

In terms of operational risks, the Group continuously strengthens its medical quality management system and internal control mechanisms, improving operational efficiency and service quality by enhancing medical quality monitoring, optimizing service processes and strengthening cost management. Meanwhile, the management will continue to monitor changes in industry policies and uncertainties in the operating environment, and adjust business strategies in a timely manner to mitigate the impact of external environmental changes on the Group's operations.

## CONTINGENT LIABILITIES

As at June 30, 2026, the Group did not have any contingent liabilities or guarantees that would have a material impact on the financial position or operations of the Group (as at December 31, 2025: nil).

## PLEDGE OF ASSETS

As at June 30, 2026, the Group did not have any material pledge of assets (as at December 31, 2025: nil).

## SUBSEQUENT EVENT(S)

The Directors are not aware of any significant event requiring disclosure that had taken place subsequent to June 30, 2026 and up to the date of this announcement.

## SIGNIFICANT INVESTMENTS

For the six months ended June 30, 2026, the Group had no significant investments.

## ACQUISITIONS AND DISPOSALS OF SUBSIDIARY(IES), ASSOCIATE(S) AND JOINT VENTURE(S)

For the six months ended June 30, 2026, the Group had no material acquisitions and disposals of subsidiary, associate and joint venture.

## FUTURE PLANS FOR MATERIAL INVESTMENT OR CAPITAL ASSETS

The Group did not have other future plans for major investments or acquisition for major capital assets at the date of this announcement, save as disclosed in the Prospectus.

## USE OF NET PROCEEDS FROM THE LISTING

With the shares of the Company (the "**Shares**") listed on the Stock Exchange on December 22, 2025, the net proceeds from the Listing (after deducting underwriting commissions, fees and estimated expenses payable by us in connection with the Listing) were approximately HK$554.5 million, which will be utilized for the purposes as set out in the prospectus. As at the date of this announcement, there was no change in the intended use of net proceeds as previously disclosed in the section headed "Future Plans and Use of Proceeds" in the Prospectus. To the extent that net proceeds are not immediately used for the intended use and to the extent permitted by the relevant law and regulations, the Company has placed the net proceeds into short-term interest-bearing accounts at licensed commercial banks and/or authorized financial institutions as defined under the Securities and Futures Ordinance or the applicable laws in the relevant jurisdiction for non-Hong Kong based deposits.

| | Approximate percentage of the net proceeds[2] | Proceeds to be used for related purpose *(HK$' million)* | Utilized proceeds during the year ended 31 December, 2025 | Utilized proceeds during the Reporting Period *(HK$' million)* | Unutilized proceeds as at June 30, 2026 *(HK$'million)* | Expected timetable for the full utilization of unutilized proceeds [1] |
|---|---|---|---|---|---|---|
| **Expansion and upgrade of our existing hospitals** | **74.3%** | **411.9** | **–** | **117.6** | **294.3** | **By end of December 2028** |
| Second-phase construction plan and the procurement of advanced medical equipment for Nanjing BenQ Hospital | 26.4% | 146.2 | – | 112.8 | 33.4 | By end of December 2027 |
| – *retainage for the construction of specialty disciplines buildings (專科樓)* | *7.2%* | *39.9* | – | *6.5* | *33.4* | *By end of December 2026* |
| – *procurement of advanced medical equipment* | *19.2%* | *106.3* | – | *106.3* | – | – |
| Third-phase and fourth-phase construction plans and the procurement of advanced medical equipment for Suzhou BenQ Hospital | 47.9% | 265.7 | – | 4.8 | 260.9 | By end of December 2028 |
| – *construction and establishment of a maternity and child center (婦幼中心)* | *30.4%* | *168.3* | – | *4.8* | *163.5* | *By end of December 2028* |
| – *procurement of advanced medical equipment* | *17.6%* | *97.4* | – | – | *97.4* | *By end of December 2028* |
| **Potential investment and mergers and acquisitions opportunities** | **16.0%** | **88.6** | **–** | **–** | **88.6** | **By end of December 2026** |
| **Upgrade of our "Smart Hospital"** | **8.0%** | **44.3** | **–** | **–** | **44.3** | **By end of December 2026** |
| **Working capital and other general corporate purposes** | **1.8%** | **9.7** | **–** | **–** | **9.7** | **By end of December 2028** |
| **Total** | **100.0%** | **554.5** | **–** | **117.6** | **436.9** | |

*Notes:*

(1) The expected timetable for the full utilization of unutilized proceeds was based on the estimate of the Group, which is subject to the current and future development of the market conditions.

(2) The sum of the figures may not add up to 100% due to rounding.

The usage of net proceeds was primarily allocated to the following projects in the first half of 2026: (1) oncology equipment for Nanjing BenQ Hospital; (2) construction payments for the Specialty discipline building of Nanjing BenQ Hospital; and (3) construction payments for the Maternal and Child Center of Suzhou BenQ Hospital.

As the Maternal and Child Center of Suzhou BenQ Hospital is still in the initial startup phase, related expenditures have been relatively low; meanwhile, the Company continues to actively seek potential investment and mergers and acquisitions opportunities.

Save as the above, there is no other change to the planned use of the net proceeds and the expected implementation timetable of the net proceeds as disclosed in the Prospectus and the 2025 annual report of the Company published on April 27, 2026.

## INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2026 (Previous Period: nil).

## MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules (the "**Model Code**") as the code of conduct regarding securities transactions by the Directors.

Upon specific enquiry to all Directors, all Directors have confirmed that they have complied with the requirements set out in the Model Code during the period from the Listing Date to the date of this announcement.

## PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the listed securities of the Company (including sale of treasury shares as defined in the Listing Rules) during the Reporting Period to the date of this announcement.

As at June 30, 2026, there were no treasury shares (as defined in the Listing Rules) held by the Company.

## CORPORATE GOVERNANCE

The Company is committed to maintaining high standards of corporate governance to safeguard the interests of the Company's Shareholders ("**Shareholders**") and to enhance corporate value and accountability. The Company has adopted the Corporate Governance Code (the "**Corporate Governance Code**") as set out in Appendix C1 to the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

During the Reporting Period, the Company complied with all code provisions set out in the Corporate Governance Code. The Company will continue to review and monitor its corporate governance practices to ensure compliance with the Corporate Governance Code.

## APPOINTMENT OF MEMBERS OF NOMINATION COMMITTEE

Under code provision B.3.5 of Part 2 of the Corporate Governance Code, the Company should appoint at least one director of a different gender to the nomination committee, and with regard to the actual circumstances of the Company, on March 9, 2026, Dr. WANG Liming (a non-executive Director) and Mr. WANG Wen-Tsung (an independent non-executive Director) have been appointed as members of the nomination committee of the Company, with effect from March 9, 2026. For further details, please refer to the announcement of the Company dated March 9, 2026.

## CHANGE IN CHIEF EXECUTIVE OFFICER

In line with the Group's overall business development direction, Ms. LO Tsui-Ling ("**Ms. Lo**") was appointed as the Chief Executive Officer of the Group (the "**CEO**") and a director of Nanjing BenQ Medical Center Co., Ltd. (南京明基醫院有限公司) ("**Nanjing BenQ Hospital**"), a wholly-owned subsidiary of the Company, with effect from July 1, 2026.

Immediately prior to Ms. Lo's appointment, Mr. HSIAO Tze-Jung ("**Mr. Hsiao**") ceased to be the CEO and a director of Nanjing BenQ Hospital with effect from July 1, 2026. Mr. Hsiao remains as an executive Director. For further details, please refer to the announcement of the Company dated June 25, 2026.

## REVIEW OF INTERIM RESULTS BY THE AUDIT COMMITTEE

The Company has established an audit committee with terms of reference in compliance with Rule 3.21 of the Listing Rules, code provision C.4 and code provision D.3 of Part 2 of the Corporate Governance Code. The audit committee consists of Mr. WANG Wen-Tsung, Dr. CHOW Hsing-Yi and Ms. HUNG Chiu-Chin, with Mr. WANG Wen-Tsung being the chairman of the committee.

The consolidated interim results of the Group for the Reporting Period have been reviewed with no disagreement by the audit committee of the Company.

## INDEPENDENT REVIEW OF AUDITOR

The interim financial report for the six months ended June 30, 2026 is unaudited, but has been reviewed by KPMG, in accordance with Hong Kong Standard on Review Engagements No. 2410, "Review of interim financial information performed by the independent auditor of the entity" issued by the Hong Kong Institute of Certified Public Accountants, whose unmodified review report is included in the interim report to be sent to the Shareholders.

## PUBLIC FLOAT

Based on the information that is publicly available to the Company and within the knowledge of the Directors, the Company has maintained a sufficient public float of the issued Shares (i.e. at least 25% of the issued Shares has been held in public hands) as required under the Listing Rules during the Reporting Period and up to the date of this announcement.

## PUBLICATION OF THE UNAUDITED INTERIM RESULTS AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.benqmedicalcenter.com). The interim report of the Group for the Reporting Period will be published on the above websites in accordance with the Listing Rules in due course.

By order of the Board
**BenQ BM Holding Cayman Corp.**
**HSIAO Tze-Jung**
*Executive Director*

Hong Kong, August 6, 2026

*As at the date of this announcement, the Board of the Company comprise: (i) Mr. HSIAO Tze-Jung as an executive Director; (ii) Mr. CHEN Chi-Hong, Ms. HUNG Chiu-Chin and Dr. WANG Liming as non-executive Directors; and (iii) Dr. CHOW Hsing-Yi, Mr. WANG Wen-Tsung and Prof. CHEN Shi-An as independent non-executive Directors.*